For treatment of inoperable
Whilst surgery is always the first option and the cornerstone of MCT management, anti-cancer medical treatment is needed when complete surgical removal is not possible or where the tumour is highly aggressive or has already spread.
Masivet® is prescribed for the treatment of non-resectable
(inoperable) high grade mast cell tumours - Patnaik grade 2 and grade 3*.
Masivet® is not a cytotoxic chemotherapy. It is a highly targeted treatment designed to work specifically and selectively on key biological pathways that cause the growth and spread of mast cell tumours.8
Masivet® is an effective, well-tolerated and proven treatment - and it was the first cancer medicine in the UK to be approved and licensed by the Veterinary Medicines Directorate for the treatment of dogs.
Masivet® acts systemically and has been shown in clinical studies to induce tumour shrinkage and to significantly prolong time to MCT progression.7
* Licensed for treatment of dogs with non-resectable mast cell tumours (Grade 2 or 3) with a confirmed mutated c-kit tyrosine kinase receptor
Masivet® is licensed for the treatment of dogs with non-resectable mast cell tumours (Grade 2 or 3)* and has been shown to have the greatest effect in those tumours with a confirmed mutated c-Kit tyrosine kinase receptor.1,7
Masivet® can be obtained from all major veterinary wholesalers in the UK and in the Republic of Ireland.
How to use Masivet®
Masivet® is a prescription-only medicine, administered in tablet form - convenient and simple to use for both pet owners and vets.
Starting dose is 12.5mg/kg once daily and the duration of treatment depends on the degree of tumour response.
Regular monthly follow-up of the treated patient must be conducted by a vet – including blood biochemistry and haematology monitoring.
For Vets - Efficacy and Safety Information
Information to discuss with your pet owners
Data sheet and references
On-line CPD & Virtual Meetings
